Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Status:
Completed
Trial end date:
2014-11-22
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with
progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer). Akt inhibitor MK2206
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.